Co-Author, Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer.
Clinical Cancer Research
Co-Author, Bisphosphonate Risks and Benefits: Finding a Balance.
Journal of Clinical Oncology
Co-Author, Are bisphosphonates ready for the adjuvant setting?
Co-Author, Pain in long-term breast cancer survivors: frequency, severity, and impact.
Co-Author, Kinetic analysis of 18F-fluoride PET images of breast cancer bone metastases.
Journal of Nuclear Medicine
Combination anastrozole and fulvestrant in metastatic breast cancer.
N. Engl. J. Med., Aug;367(5):435-44 (2012)
A prospective analysis of the influence of older age on physician and patient decision-making when considering enrollment in breast cancer clinical trials (SWOG S0316).
Oncologist., 17(9):1180-90 (2012)
Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial.
Lancet Oncol., Jul;13(7):734-42 (2012)
Hypnosis for symptom management in women with breast cancer: a pilot study.
Int J Clin Exp Hypn., Apr;60(2):135-59 (2012)
Phase II trial of simple oral therapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: SWOG S0430.
Oncologist., 17(2):179-87 (2012)
Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer.
J. Clin. Oncol., Dec;29(34):4491-7 (2011)
Can we predict who's at risk for developing bone metastases in breast cancer?
J. Clin. Oncol., Sep;29(27):3600-4 (2011)
How do we define efficacy in comparing osteoclast-targeted agents in metastatic breast cancer?
J. Clin. Oncol., Sep;29(26):3591-2; author reply 3592-3 (2011)
SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer.
Breast Cancer Res. Treat., Nov;130(1):123-31 (2011)
Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221).
Breast Cancer Res. Treat., Dec;130(3):993-1002 (2011)
Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer.
Clin. Cancer Res., Jul;17(14):4799-805 (2011)
Axillary vs sentinel lymph node dissection for invasive breast cancer.
JAMA., Jun;305(22):2290; author reply 2290-1 (2011)
Breast cancer management in low resource countries (LRCs): consensus statement from the Breast Health Global Initiative.
Breast., Apr;20 Suppl 2:S3-11 (2011)
Problem solving for breast health care delivery in low and middle resource countries (LMCs): consensus statement from the Breast Health Global Initiative.
Breast., Apr;20 Suppl 2:S20-9 (2011)
PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake.
Clin. Cancer Res., Apr;17(8):2400-9 (2011)